Ardea Biosciences — Corporate Update (January 2011)
13 slides from Ardea Biosciences's corporate update, Jan 6, 2011
Slide 1: Ardea Biosciences Company Update
Ardea Biosciences Company Update January 6, 2011
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Status of Development Programs
Status of Development Programs Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 MEKI for cancer 3 Gout RDEA594 Next Generation MEKI + sorafenib for cancer RDEA119 RDEA119 Gout
Slide 4: US Gout Patient Distribution
US Gout Patient Distribution 4 Diagnosed Gout 8 M* ~90% ~50% ~50% Allopurinol Treated 2.5 M Responders (sUA<6mg/dL) 1.25 M Severe Chronic Gout 0.1 - 0.3M Allopurinol Inadequate-Responders 1.25 M ~10-20% Small % Allopurinol Intolerant Gout Pts on urate lowering therapy 2.6 M Small % Education (DTC) I
Slide 5: Almost Half of Patients Under Treatment are Still Having Flares
Almost Half of Patients Under Treatment are Still Having Flares - Lower sUA Reduces Flares Physicians believe that approximately half of the 2.6M patients receiving treatment are still having flares* This is consistent with less than half of patients reaching target sUA on allopurinol sUA of inadequ
Slide 6: RDEA594 - Clinical Summary
RDEA594 - Clinical Summary 6 Study 201 Phase 2a combination with allopurinol Combination with RDEA594 400 mg produced 100% response for sUA < 6 mg/dL Lower rate of abnormal laboratory values on RDEA594 than control Study 110 Phase 1b PK/PD combination with allopurinol Combination with RDEA594 600 mg
Slide 7: Phase 2b Combination Study with Allopurinol in Allopurinol-Refractory Patients
Placebo RDEA594 Phase 2b Combination Study with Allopurinol in Allopurinol-Refractory Patients 2-4 weeks 4 weeks 2 weeks Population: 208 gout patients with serum urate (sUA) ^ 6 mg/dL while receiving a stable dose of allopurinol for at least 6 weeks Duration: 4-week double-blind treatment period wit
Slide 8: Primary Endpoint - Mean Percent Change in Serum Urate at Week 4
(CHART) Primary Endpoint - Mean Percent Change in Serum Urate at Week 4 p<0.0001 8 ITT Population p<0.0001 p<0.0001 Baseline sUA = 6.7 6.4 6.9 7.3 (mg/dL) P-values are for comparison to placebo group using an ANCOVA model
Slide 9: Percent of Patients with Serum Urate <6 mg/dL at Week 4
(CHART) Percent of Patients with Serum Urate < 6 mg/dL at Week 4 9 n = 72 46 42 48 P<0.0001 P<0.0001 P<0.0001 ITT Analysis* *Intent-to-treat analysis considers patients' without Week 4 results as failures, regardless of the reason for the missing data P-values are for comparison to allopurinol alone
Slide 10: Percent of Patients with Serum Urate <6 mg/dL at Last Visit
(CHART) Percent of Patients with Serum Urate < 6 mg/dL at Last Visit 10 LOCF analysis used in febuxostat US package insert* n = 70 45 42 42 P<0.0001 P<0.0001 P<0.0001 *Last observation carried forward analysis uses a prior week's sUA results when Week 4 results are missing P-values are for compariso
Slide 11: Incidence of the Most Frequent Adverse Events
Incidence of the Most Frequent Adverse Events* 11 Adverse Events Allopurinol + RDEA594 Dose Group Allopurinol + RDEA594 Dose Group Allopurinol + RDEA594 Dose Group Allopurinol + RDEA594 Dose Group Allopurinol + RDEA594 Dose Group Allopurinol + RDEA594 Dose Group Allopurinol + RDEA594 Dose Group Allo
Slide 12: Safety Summary
Safety Summary 12 Laboratory Adverse Events* Allopurinol + RDEA594 Dose Allopurinol + RDEA594 Dose Allopurinol + RDEA594 Dose Allopurinol + RDEA594 Dose Allopurinol + RDEA594 Dose Allopurinol + RDEA594 Dose Allopurinol + RDEA594 Dose Allopurinol + Laboratory Adverse Events* 200mg (N=46)n (%) 400mg (
Slide 13: Study Summary
Study 203 Summary In patients not adequately responding to allopurinol, addition of RDEA594 produced statistically and clinically relevant reductions in sUA All three doses of RDEA594 produced reductions in sUA that were significantly superior to allopurinol alone (p<0.0001) All three doses of RDEA5